Chemistry:Bocidelpar
Bocidelpar (INN, USAN; developmental code names ASP-0367, MA-0211, and MTB-1) is a peroxisome proliferator-activated receptor delta (PPARδ) agonist which is or was under development for the treatment of mitochondrial myopathies, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), Duchenne muscular dystrophy, and metabolic disorders.[1][2][3][4][5] It is taken orally.[1][3]
The clinical pharmacodynamics and pharmacokinetics of bocidelpar have been studied.[4][5]
Bocidelpar was originated by Mitobridge and is under development by Astellas Pharma and Mitobridge.[1][2][3] As of February 2026, bocidelpar is in phase 2/3 clinical trials for mitochondrial myopathies and phase 2 trials for ME/CFS, whereas no recent development has been reported for Duchenne muscular dystrophy or metabolic disorders.[1] However, other sources state that bocidelpar has been discontinued.[2][3] The drug was also under development for the treatment of hypoxia, but development for this indication was discontinued.[1] A phase 2 trial for mitochondrial myopathies was terminated due to lack of effectiveness.[1]
See also
- List of investigational ME/CFS drugs
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 "Bocidelpar". 28 February 2026. https://adisinsight.springer.com/drugs/800050069.
- ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Bocidelpar with Synapse". 27 February 2026. https://synapse.patsnap.com/drug/62054084f4d742d4b4284bfd3a6ab4f2.
- ↑ 3.0 3.1 3.2 3.3 "Bocidelpar Drug Profile". 1 January 1900. https://pryzm.ozmosi.com/product/21219.
- ↑ 4.0 4.1 "Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study". Muscle & Nerve 65 (1): 110–120. January 2022. doi:10.1002/mus.27436. PMID 34642949.
- ↑ 5.0 5.1 "Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies". Clinical and Translational Science 18 (8). August 2025. doi:10.1111/cts.70310. PMID 40748778.
 |  |
